Acrivon uses its proprietary AP3 proteomics platform to create quantitative OncoSignature tests that directly measure tumor‑driving protein pathways from biopsy samples. These tests serve as companion diagnostics to match patients with Acrivon's kinase inhibitor candidates, improving patient selection and accelerating clinical development for oncology drug developers.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current precision oncology relies heavily on genomic biomarkers, which often fail to capture the functional protein activity driving tumor growth, leading to suboptimal patient selection for targeted therapies. This limits the effectiveness of drugs, especially in cancers with multiple driver mutations and complex resistance mechanisms.
Solution
Acrivon leverages its proprietary AP3 platform, a proteomics‑based precision medicine system, to develop quantitative OncoSignature tests that measure tumor‑driving protein pathways directly from biopsy samples. By integrating high‑resolution mass spectrometry with automated tissue imaging, AP3 identifies drug‑specific protein signatures independent of genetic alterations. These signatures are used as companion diagnostics to match patients with Acrivon’s kinase inhibitors—such as the CHK1/2 inhibitor ACR‑368, the dual WEE1/PKMYT1 inhibitor ACR‑2316, and a CDK11‑targeting candidate—thereby enriching clinical trials with responders and enabling accelerated approval pathways. The platform also uncovers additional cancer indications, informs rational combination strategies, and reveals pharmacodynamic and resistance biomarkers to guide dosing and trial design.
Target Audience
Primary customers are oncology drug developers and clinical trial sponsors seeking proteomics‑driven patient selection, as well as oncologists and cancer centers enrolling patients in precision‑medicine trials.
Features
- High‑resolution mass spectrometry for unbiased identification of protein biomarkers linked to drug mechanisms
- Automated tumor‑biopsy imaging assay that quantifies protein signatures (OncoSignature tests) on pretreatment samples
- Drug‑specific companion diagnostics that predict patient response independent of underlying genetic mutations
- Ability to discover new sensitive cancer indications and rational combination regimens based on proteomic profiling
- Generation of pharmacodynamic and resistance biomarkers to optimize dosing and trial endpoints
- Application across Acrivon’s pipeline of DNA damage response, cell‑cycle, and transcriptional regulator inhibitors